DK0984938T3 - Cyanoguanidiner som celleproliferationsinhibitorer - Google Patents

Cyanoguanidiner som celleproliferationsinhibitorer

Info

Publication number
DK0984938T3
DK0984938T3 DK98924055T DK98924055T DK0984938T3 DK 0984938 T3 DK0984938 T3 DK 0984938T3 DK 98924055 T DK98924055 T DK 98924055T DK 98924055 T DK98924055 T DK 98924055T DK 0984938 T3 DK0984938 T3 DK 0984938T3
Authority
DK
Denmark
Prior art keywords
stands
alkoxycarbonyl
trifluoromethyl
carboxy
cyano
Prior art date
Application number
DK98924055T
Other languages
Danish (da)
English (en)
Inventor
Charlotte Schou
Original Assignee
Leo Pharma As With Secondary N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As With Secondary N filed Critical Leo Pharma As With Secondary N
Application granted granted Critical
Publication of DK0984938T3 publication Critical patent/DK0984938T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98924055T 1997-05-29 1998-05-15 Cyanoguanidiner som celleproliferationsinhibitorer DK0984938T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711125.6A GB9711125D0 (en) 1997-05-29 1997-05-29 Novel cyanoguanidines
PCT/DK1998/000196 WO1998054144A1 (en) 1997-05-29 1998-05-15 Cyanoguanidines as cell proliferation inhibitors

Publications (1)

Publication Number Publication Date
DK0984938T3 true DK0984938T3 (da) 2004-01-12

Family

ID=10813255

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98924055T DK0984938T3 (da) 1997-05-29 1998-05-15 Cyanoguanidiner som celleproliferationsinhibitorer

Country Status (20)

Country Link
US (1) US6346541B1 (cs)
EP (1) EP0984938B1 (cs)
JP (1) JP4408455B2 (cs)
KR (1) KR100496220B1 (cs)
CN (1) CN1116283C (cs)
AT (1) ATE249438T1 (cs)
AU (1) AU733142B2 (cs)
CA (1) CA2292895C (cs)
CZ (1) CZ294842B6 (cs)
DE (1) DE69818041T2 (cs)
DK (1) DK0984938T3 (cs)
ES (1) ES2206932T3 (cs)
GB (1) GB9711125D0 (cs)
HU (1) HUP0002921A3 (cs)
NZ (1) NZ501071A (cs)
PL (1) PL190314B1 (cs)
PT (1) PT984938E (cs)
RO (1) RO120541B1 (cs)
RU (1) RU2195453C2 (cs)
WO (1) WO1998054144A1 (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
AU4080300A (en) 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU1494702A (en) 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs
IL158574A0 (en) 2001-05-24 2004-05-12 Leo Pharma As Novel pyridyl cyanoguanidine compounds
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
EP1507760B1 (en) * 2002-05-17 2007-08-01 Leo Pharma A/S Cyanoguanidine prodrugs
MXPA04011324A (es) * 2002-05-17 2005-02-17 Leo Pharma As Profarmacos de cianoguanidina.
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
WO2006037468A1 (en) * 2004-09-30 2006-04-13 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv reverse transcriptase inhibitors
JP5189367B2 (ja) 2004-12-22 2013-04-24 レオ ファーマ アクティーゼルスカブ 新規シアノグアニジン化合物
JP2008535822A (ja) * 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
EP2197443A4 (en) 2007-09-26 2014-01-01 Gemin X Pharmaceuticals Canada Inc COMPOSITIONS AND METHOD FOR LEADING NAD + MIRRORS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE HEMMER
US8173677B2 (en) 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
WO2009086835A1 (en) * 2008-01-11 2009-07-16 Topotarget A/S Novel cyanoguanidines
WO2010023307A1 (en) 2008-08-29 2010-03-04 Topotarget A/S Novel urea and thiourea derivatives
AU2010210248B2 (en) * 2009-02-06 2012-08-16 Tianjin Hemay Bio-Tech Co., Ltd. Pharmaceutical compositions comprising pyridyl cyanoguanidine, process for preparing the same and use thereof
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
MX342838B (es) 2010-09-03 2016-10-14 Forma Tm Llc * Compuestos y composiciones de guanidina para la inhibicion de nampt.
WO2012055346A1 (zh) 2010-10-26 2012-05-03 天津和美生物技术有限公司 N-(6-(4-氯苯氧基)己基)-n'-氰基-n''-(4-吡啶基)胍的多晶型物及其制备和应用
US11638762B2 (en) 2016-10-18 2023-05-02 Seagen Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
CA3060206A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4530693A (en) * 1992-08-13 1994-03-15 Upjohn Company, The Cyanoguanidines as potassium channel blockers
GB9219472D0 (en) * 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
EP0741708B1 (en) * 1994-01-28 1998-05-20 PHARMACIA & UPJOHN COMPANY Cyanoguanidines as k-channel blockers

Also Published As

Publication number Publication date
ES2206932T3 (es) 2004-05-16
EP0984938A1 (en) 2000-03-15
HUP0002921A3 (en) 2002-10-28
EP0984938B1 (en) 2003-09-10
GB9711125D0 (en) 1997-07-23
DE69818041T2 (de) 2004-07-08
CZ294842B6 (cs) 2005-03-16
CN1116283C (zh) 2003-07-30
CN1258279A (zh) 2000-06-28
CA2292895A1 (en) 1998-12-03
HUP0002921A2 (hu) 2001-01-29
PT984938E (pt) 2004-02-27
CZ9904234A3 (cs) 2001-02-14
DE69818041D1 (de) 2003-10-16
PL190314B1 (pl) 2005-11-30
JP2001526694A (ja) 2001-12-18
NZ501071A (en) 2001-08-31
PL337030A1 (en) 2000-07-31
KR100496220B1 (ko) 2005-06-21
HK1027562A1 (en) 2001-01-19
JP4408455B2 (ja) 2010-02-03
ATE249438T1 (de) 2003-09-15
CA2292895C (en) 2007-03-06
WO1998054144A1 (en) 1998-12-03
AU733142B2 (en) 2001-05-10
US6346541B1 (en) 2002-02-12
RO120541B1 (ro) 2006-03-30
AU7638698A (en) 1998-12-30
KR20010013148A (ko) 2001-02-26
RU2195453C2 (ru) 2002-12-27

Similar Documents

Publication Publication Date Title
DK0984938T3 (da) Cyanoguanidiner som celleproliferationsinhibitorer
DE69928697D1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
WO2006109075A3 (en) Hydroxybenzamide derivatives and their use as inhibitors of hsp90
DK1109785T3 (da) Indolderivater og deres anvendelse til behandling af ondartede og andre sygdomme forårsaget af patologisk celleproliferation
DE60335869D1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
NO20065948L (no) Quinazolin-4-yl-piperidin- and cinnolin-4-yl-piperidin-derivatives som PDE10-inhibitorer for behandling av CNS forstyrrelser
AR039566A1 (es) Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion
NZ508990A (en) Pyrazoline derivatives, their preparation and application as medicaments
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
NO20051051L (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler
BG103867A (en) Cyanoguanidines as cell proliferation inhibitors
TW200510311A (en) CCr8 inhibitors
CO6311102A2 (es) Derivados carboxílicos y alcoxi de 4-sustituido-2-[4-({(5-metil-1h-pirrol -2-il) carbonil} amino)- piperidin sustituido -1-il]-1,3-tiazol como inhibidores de dna girasa y/o topoisomerasa iv y composiciones farmacéuticas de los mismos
BR0212925A (pt) Derivados de idol como inibidores de cox ii
WO2004022528A3 (en) Arylglycine derivatives and their use as glycine transport inhibitors
DK0984936T3 (da) Cyanoguanidiner som celleproliferationsinhibitorer
WO2002014281A8 (en) Pyridine derivatives as inhibitors of p38
NO20000957L (no) Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer
DK1673354T3 (da) Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister
HRP20050382A2 (en) Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
NO20061789L (no) Aminopyridinderivater som induserbare NO-syntaseinhibitorer
EA200601589A1 (ru) Производные 7h-8,9-дигидропирано-(2,3-c)имидазо(1,2a)пиридина и их применение в качестве ингибиторов секреции кислоты желудочного сока